Next-Generation Benchtop Diagnostic Platform Delivers Rapid Multi-Gene Test Results
Posted on 27 Nov 2023
In today’s rapidly advancing healthcare sector, the implementation of multi-gene testing is increasingly crucial. This method efficiently uses limited tissue samples and significantly speeds up the time to get critical results. Now, a benchtop diagnostic platform for fully integrated analysis of molecular biomarker signatures with a 4-hour automated workflow allows hospitals and pathology labs to bring this advanced technology in-house, leading to quicker results and enhanced coordination in patient care.
BIOTYPE GmbH (Dresden, Germany) has significantly upgraded its MODAPLEX platform, making it easier for research and clinical labs to conduct sophisticated molecular analyses swiftly and automatically. The MODAPLEX system stands out for its ability to simultaneously detect and assess crucial biomarkers using a simple process. With an efficient workflow that takes less than four hours, the platform provides pathologists and clinicians with rapid and precise results. It enables the simultaneous measurement of key RNA and DNA biomarkers from a single sample, facilitating prompt initiation of optimal therapy and contributing to healthcare system efficiency.
BIOTYPE is now introducing an enhanced version of its hardware platform, featuring simplified software for automated analysis of cancer-related RNA and DNA biomarkers. The open-system nature of the MODAPLEX platform allows third parties, including molecular testing system developers and pharmaceutical companies, to create and distribute their own assays. This strategy broadens the range of available tests and makes the MODAPLEX platform more appealing to users who prefer sourcing test kits from various providers.
"The launch of the next-generation MODAPLEX system also marks our entry into the international business for molecular testing platforms," said Dr Norman Gerstner, CEO of BIOTYPE GmbH. "Last year, we repositioned the company in the rapidly growing precision medicine market. In addition to molecular tests for highly specialized diagnostics of complex diseases, we are now expanding our portfolio to include software and instruments. In addition, MODAPLEX is making an important contribution to meeting the growing demand for sophisticated technologies for multi-gene testing. MODAPLEX maximizes the use of existing tissue samples and reduces critical turnaround times."
Related Links:
BIOTYPE GmbH
